Managing the acutely agitated and psychotic patient

CNS Spectrums

Volumn 12, Issue 10 SUPPL. 17, 2007, Pages 5-11

  Nordstrom, Kimberly ^a,b   Allen, Michael H ^c  

^a Yampa Valley Medical Center ^*  (United States)

^b Yampa Valley Medical Center   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

AGGRESSION; AGITATED DEPRESSION; AGITATION; ALCOHOL WITHDRAWAL; BEHAVIOR DISORDER; BIPOLAR DISORDER; BORDERLINE STATE; BRADYCARDIA; BRIEF PSYCHIATRIC RATING SCALE; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DELIRIUM; DOPAMINERGIC SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EMERGENCY CARE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPOTENSION; INTOXICATION; MEDICAL ASSESSMENT; MEDICAL ERROR; MENTAL PATIENT; MONOTHERAPY; NAUSEA AND VOMITING; OBESITY; PANIC; PARKINSONISM; PATIENT CARE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SLEEP APNEA SYNDROME; STANDING; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 36048972607     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900026286     Document Type: Review

References (48)

1. Hazlett SB, McCarthy ML, Londner MS, Onyike CU. Epidemiology of adult psychiatric visits to US emergency departments. Acad Emer Med. 2004;11(2):193-195.
2. Dhossche DM, Ghani SO. Who brings patients to the psychiatric emergency room? Psychosocial and psychiatric correlates. Gen Hosp Psychiatry. 1998;20(4):235-240.
3. Moore GP, Jackimczyk KC. The violent patient. In: Rosen P, Barkin R, ed. Emergency Medicine Concepts and Clinical Practice. Vol 3. St. Louis, Mo: CV Mosby Co; 1998.
4. Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry. 2004;26(1):42-49.
5. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry. 2000;61(suppl 14):5-10.
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med. 2005;353(12):1209-1223.
7. Corrigan JD. Development of a scale for assessment of agitation following traumatic brain injury. J Clin Exp Neuropsychol. 1989;11(2):261-277.
8. Kay SR, Fiszbein A, Opler LA. The positive and negative symptom scale (PANSS) for schizophrenia. Schizophr Bulletin. 1987;13(2):261-276.
9. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812.
10. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143(1):35-39.
11. Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP. Validation of the behavioral activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87-95.
12. De Fruyt J, Demyttenaere K. Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. Eur Psychiatry. 2004;19(5):243-249.
13. Damsa C, Ikelheimer D, Adam E, et al. Heisenberg in the ER: observation appears to reduce involuntary intramuscular injections in a psychiatric emergency service. Gen Hosp Psychiatry. 2006;28(5):431-433.
14. Schillerstrom TL, Schillerstrom JE, Taylor SE. Laboratory findings in emergently medicated psychiatry patients. Gen Hosp Psychiatry. 2004;26(5):411-414.
15. Chevrolet JC, Jolliet P. Clinical review: Agitation and delirium in the critically ill - significance and management. Crit Care. 2007;11(3):214.
16. Damsa C, Adam E, De Gregorio F, et al. Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room. Gen Hosp Psychiatry. 2007;29(1):51-53.
17. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005. The expert consensus guideline series treatment of behavioral emergencies. J Psychiatr Pract. 2005;11(suppl 1):5-108.
18. National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London, UK: National Institute for Clinical Excellence (NICE); 2002.
19. Allen MH, Carpenter D, Sheets JL, Miccio S, Ross R. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract. 2003;9(1):39-58.
20. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61(suppl 14):11-20.
21. Allen MH, Currier GW, Hughes DH, Docherty JP, Carpenter D, Ross R. Treatment of Behavioral Emergencies: A Summary of the Expert Consensus Guidelines. J Psych Pract. 2003;9(1):16-38.
22. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61(suppl 14):11-20.
23. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind emergency department study. Am J Emerg Med. 1997;15(4):335-340.
24. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment in psychotic agitation. J Clin Psychiatry. 2001;62(3):153-157.
25. Veser FH, Veser BD, McMullan JT, Zealberg J, Currier GW. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. J Psychiatr Pract. 2006;12(2):103-108.
26. Yoshimura R, Shinkai K, Ueda N, Nakamura J. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients. Pharmacopsychiatry. 2007;40(1):9-13.
27. De Deyn PP, Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. Eur Psychiatry. 2006;21(1):21-28.
28. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette Syndrome. Neurology. 2003;60(7):1130-1135.
29. Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther. 2003;25(2):530-541.
30. Pae CU, Kim JJ, Lee CU, et al. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. J Clin Psychiatry. 2007;68(3):399-405.
31. Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. J Psychiatr Pract. 2006;12(4):223-228.
32. Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr. 2005;10(9):1-15.
33. Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry. 2004;16(3):145-154.
34. Brooks S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. J Clin Psychiatry. 2003;64(suppl 19):13-18.
35. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comsparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology. 2005;178(4):514-523.
36. Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel FS. Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. J Clin Psychiatry. 2006;67(4):638-642.
37. Preval H, Klotz SG, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry. 2005;27(2):140-144.
38. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441-448.
39. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):1149-1151.
40. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21(4):389-397.
41. Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry. 2001;62(suppl 2):22-24.
42. Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry. 2001;62(suppl 2):17-21.
43. Canas F. Management of agitation in the acute psychotic patient - efficacy without excessive sedation. Eur Neuropsychopharmacol. 2007;17(suppl 2):108-114.
44. Currier GW, Citrome LL, Zimbroff DL, et al. Intramuscular aripiprazole in the control of agitation. J Psychiatr Pract. 2007;13(3):153-169.
45. Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007;68(5):662-668.
46. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(1):111-119.
47. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 2006;88(3):281-292.
48. Daniel DG, Currier GW, Zimbroff DL, et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. J Psychiatr Pract. 2007;13(3):170-177.